BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fidaxomicin regulatory update

FDA granted Orphan Drug designation for Optimer's fidaxomicin to treat Clostridium difficile infection (CDI) in patients <=16 years of age. In November, Optimer completed...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >